Although ICIs are effective in cases with high tumor mutation burden and high programmed death‐ligand 1 (PD‐L1) expression, the establishment of biomarkers that can more accurately predict treatment outcome is necessary as ICIs potentially have serious adverse events and are costly.10 Here, CD274 is linked to neoplasm.